Ziwei Huang
Name of Research Group: Nano-Bio Technology Laboratory
Description of Research Group:Biomedical engineering, the most rapidly growing of engineering disciplines from a global perspective, is now playing an irreplaceable role in the enhancement of human lifespan and its quality. At our Nano-Bio Technology Laboratory, we explore multi-disciplinary research and cutting-edge technology so that we bridge medicine and technology. Specifically, we are dedicated to achieving similar success with polypeptide sequencing to what nanopore sequencing has done to DNA so that there will be a possibility that we understand the causes of protein primary structure related diseases better and consequently come up with a solution. Moreover, solid-state nanopores have huge potential in single cell secretion detection because significant clinical biomarkers can be selective thanks to nanopore's adjustable geometry. We are also interested in utilizing electron microscopy and atomic force microscopy in various biomedical applications, such as synthetic biology and virology, to aid clinic treatment.
Team members Introduction:Ziwei Huang, master student (Class 2023) in Biomedical Engineering and Technology, Central South University. He graduated from Nankai University in June 2021 with major in biology science. During his undergraduate study, he concentrated in microbiology, biochemistry and other courses, and published one relevant scientific paper. In addition, he paid attention to the cultivation of practical ability and innovation ability of biological experiments. He also participated in Tianjin Innovation and Entrepreneurship Competition. Email: 9535252215@qq.com Publications: Anti-neuroinflammatory effects of dimethylaminomylide (DMAMCL, i.e., ACT001) are associated with attenuating the NLRP3 inflammasome in MPTP-induced Parkinson disease in mice. Behav Brain Res. 2020.
